HMS Capital Management LLC Invests $477,000 in United Therapeutics Co. (NASDAQ:UTHR)

HMS Capital Management LLC purchased a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,331 shares of the biotechnology company's stock, valued at approximately $477,000.

Several other hedge funds have also added to or reduced their stakes in the company. ClariVest Asset Management LLC grew its stake in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC acquired a new position in United Therapeutics during the second quarter valued at approximately $30,000. Innealta Capital LLC bought a new stake in United Therapeutics in the second quarter valued at approximately $33,000. USA Financial Formulas acquired a new stake in United Therapeutics in the third quarter worth $33,000. Finally, Values First Advisors Inc. bought a new position in shares of United Therapeutics during the third quarter worth $90,000. Institutional investors own 94.08% of the company's stock.

Insiders Place Their Bets

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm's stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $328.39, for a total transaction of $1,182,204.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company's stock, valued at $42,690.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Christopher Causey sold 510 shares of the business's stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the sale, the director now directly owns 3,675 shares in the company, valued at $1,384,115.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $328.39, for a total value of $1,182,204.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at $42,690.70. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 85,022 shares of company stock valued at $30,412,032 over the last 90 days. 11.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on UTHR shares. The Goldman Sachs Group raised their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research note on Friday, November 1st. Argus increased their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. HC Wainwright lifted their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Oppenheimer increased their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Finally, Morgan Stanley cut shares of United Therapeutics from an "overweight" rating to an "equal weight" rating and boosted their price objective for the company from $310.00 to $321.00 in a research report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, United Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $370.86.

United Therapeutics Stock Up 3.8 %

Shares of NASDAQ UTHR traded up $14.72 during trading hours on Wednesday, hitting $397.49. The company had a trading volume of 467,049 shares, compared to its average volume of 465,136. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $399.23. The firm's 50 day moving average is $356.67 and its 200-day moving average is $319.83. The stock has a market capitalization of $17.75 billion, a P/E ratio of 16.81, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter last year, the firm posted $5.38 EPS. On average, sell-side analysts predict that United Therapeutics Co. will post 25.57 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.